Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earning Presentation for the Q2 & H1 FY 2402-11-2023
02-11-2023
Dr. Lal PathLabs Ltd - 539524 - Authorization For Determining Materiality Of Event/ Information
Authorization for determining materiality of event/ information02-11-2023
Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Financial Results For The Quarter And Half Year Ended September 30, 2023
Outcome of Board Meeting for approval of Financial Results for the Quarter and Half Year ended September 30, 202302-11-2023
Dr. Lal PathLabs Ltd - 539524 - Financial Results For The Quarter And Half Year Ended September 30, 2023
Financial Results for the Quarter and Half Year ended September 30, 202302-11-2023
Dr. Lal Pathlabs Share Price Live blog for 01 Nov 2023
Dr. Lal Pathlabs stock price went up today, 01 Nov 2023, by 2.6 %. The stock closed at 2364.6 per share. The stock is currently trading at 2426.1 per share. Investors should monitor Dr. Lal Pathlabs stock price closely in the coming days and weeks to see how it reacts to the news.01-11-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings31-10-2023
Dr. Lal Pathlabs Share Price Live blog for 31 Oct 2023
Dr. Lal Pathlabs stock price went up today, 31 Oct 2023, by 1.01 %. The stock closed at 2364.6 per share. The stock is currently trading at 2388.45 per share. Investors should monitor Dr. Lal Pathlabs stock price closely in the coming days and weeks to see how it reacts to the news.31-10-2023
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, please find attached the invite of the Conference Call for Investors/ Analysts to be held on Thursday, November 02, 2023 at 4:30 P.M. (IST) to discuss the financial and operating performance for Q2 & H1 FY2426-10-2023
Dr. Lal PathLabs Ltd - 539524 - Board Meeting Intimation for Approval Of Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended September 30, 2023
Dr. Lal Pathlabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 ,inter alia, to consider and approve unaudited (standalone and consolidated) financial results for the Quarter and Half Year ended September 30, 2023.25-10-2023
Dr Lal PathLabs sheds 3% after Goldman Sachs downgrades stock to 'sell'
Goldman forecasts a structural decline in volumes to high single digits from the previous estimate of double-digit volume growth. The firm has also said that the valuations of the B2C incumbent are stretched.19-10-2023